ATLASProtalix BioTherapeutics (PLX) earnings date: Nov 12, 2026
Protalix BioTherapeutics (PLX) reports earnings for the quarter ended Sep 30, 2026 on Thu, Nov 12, 2026, before the open. Analysts expect EPS of -$0.02.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on PLX
| Last price | $2.59 (-0.8%) |
|---|---|
| Normal 1-day range (±1σ) | ±2.6% |
| Earnings beat history | Beat the EPS estimate in 2 of the last 4 reports |
These figures come from the same calibrated model and valuation as the Protalix BioTherapeutics stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Protalix BioTherapeutics reports on Nov 12, 2026. One email the day before, with ATLAS’s read on Protalix BioTherapeutics. You can switch it off at any time.
Alert me before PLX reportsFree to start. Creating an account takes under a minute.
PLX earnings at a glance
| Next report (confirmed) | Thu, Nov 12, 2026 |
|---|---|
| Time | Before the open |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$0.02 |
| Last report | Aug 12, 2026 · Beat |
| Beat rate (last 4 reports) | 2 of 4 (50%) |
| Average EPS surprise | -60.8% |
| Average move around a report | ±9.3% (last 4) |
| Sector | Healthcare · Biotechnology |
Protalix BioTherapeutics earnings history: last 4 reports
Protalix BioTherapeutics last reported on Aug 12, 2026: EPS of $0.05 against an estimate of -$0.01 (+600.0% surprise), a beat.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 12, 2026 | -$0.01 | $0.05 | +600.0% | Beat | -2.9% |
| May 6, 2026 | $2.55 | $2.72 | +6.7% | Beat | +1.0% |
| Mar 18, 2026 | $0.01 | -$0.07 | -800.0% | Miss | -20.1% |
| Nov 13, 2025 | $0.06 | $0.03 | -50.0% | Miss | -13.1% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for PLX
See the fair value, the probability range and the earnings history of Protalix BioTherapeutics on its ATLAS page.
Protalix BioTherapeutics (PLX) stock analysisPlans from €3.99 a month.
Protalix BioTherapeutics earnings: frequently asked questions
When does Protalix BioTherapeutics (PLX) report earnings?
Protalix BioTherapeutics is scheduled to report on Thursday, November 12, 2026, before the open. ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for PLX?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$0.02 per share (USD). Estimates can change before the report.
How often does PLX beat earnings estimates?
Of its last 4 reports with a recorded result, Protalix BioTherapeutics beat the EPS estimate 2 times; the average surprise was -60.8%. Past results do not predict the next one.
How much does PLX move around earnings?
Over its last 4 reports the stock moved an average of 9.3% (absolute, from the close before the report day to the close after it), and finished higher 1 of 4 times.
Did Protalix BioTherapeutics beat earnings estimates last quarter?
Protalix BioTherapeutics last reported on Aug 12, 2026: EPS of $0.05 against an estimate of -$0.01 (+600.0% surprise), a beat.
How much does PLX usually move in a day?
On a normal trading day the ATLAS model puts PLX’s one-day range at about ±2.6%, with a 50% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Thu, Nov 12, 2026
Educational information, not investment advice. Disclaimer